Nexalin Technology, Inc. (NXL)

Market Cap	36.91M
Revenue (ttm)	162,078
Net Income (ttm)	-5.55M
Shares Out	12.86M
EPS (ttm)	-0.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	301,663
Open	3.250
Previous Close	3.240
Day's Range	2.850 - 3.283
52-Week Range	0.302 - 4.490
Beta	4.26
Analysts	Hold
Price Target	n/a
Earnings Date	Mar 26, 2025

About NXL

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer’s disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The compan...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Sep 16, 2022
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: NXL
• Website: https://www.nexalin.com

Financial Performance

In 2023, Nexalin Technology's revenue was $110,748, a decrease of -91.62% compared to the previous year's $1.32 million. Losses were -$4.65 million, 173.8% more than in 2022.